Non-Hodgkin lymphoma includes more than 60 types of blood cancer affecting white blood cells called lymphocytes. Some types grow slowly and may not need treatment right away, while others are aggressive and require immediate chemotherapy or newer targeted drugs. Treatment depends on the specific type, stage, and whether the cancer has certain genetic markers.
What's actually going on in research
Trials are testing CAR T-cell therapy for more types of lymphoma, bispecific antibodies that connect T-cells to cancer cells, antibody-drug conjugates that deliver chemotherapy directly to tumors, and combinations that might replace traditional chemotherapy. Researchers are also studying ways to predict who will respond to which treatment and how to manage disease that returns after initial treatment.
CAR T-cell therapy expansion
CAR T-cell therapy is now approved for several types of lymphoma after other treatments fail. Trials are testing it earlier in treatment and for additional lymphoma types.
Bispecific antibodies
These drugs connect a person's own T-cells directly to lymphoma cells, forcing an immune attack. Several have been approved recently, and trials are testing them in combination and earlier in treatment.
Chemotherapy-free regimens
Some trials combine targeted drugs and immunotherapies to avoid traditional chemotherapy. Early results suggest similar outcomes with fewer side effects for certain lymphoma types.
What to know before you search
Eligibility typically depends on lymphoma type, stage, prior treatments, genetic markers like CD20 or CD19 expression, and organ function.
What types of trials are currently open
- Targeted therapy trials — Testing drugs that attack specific proteins on lymphoma cells, often combined with chemotherapy or other targeted drugs.
- Immunotherapy trials — Testing CAR T-cell therapy, bispecific antibodies, and checkpoint inhibitors that help the immune system recognize and attack lymphoma.
- Combination trials — Testing whether combining newer drugs with standard chemotherapy or with each other works better than current treatment.
- Maintenance trials — Testing whether taking a drug after initial treatment keeps lymphoma from returning.
- Relapsed disease trials — Testing treatments specifically for lymphoma that has returned or did not respond to initial therapy.
Recently added Non-hodgkin Lymphoma trials
Take a modified chemotherapy regimen for relapsed lymphoma
This Phase III randomized controlled trial evaluates the effectiveness and toxicity profile of a modified DHAP regimen compared to the standard DHAP regimen in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The DHAP regimen (cisplatin, cytarabine, dexamethasone) is widely used as salvage therapy but is associated with significant toxicities, including renal dysfunction and severe myelosuppression. The modified DHAP protocol fractionates cisplatin and cytarabine administration to reduce nephrotoxicity, improve tolerability, and potentially allow outpatient treatment. A total of 74 patients will be randomized (37 per arm) to receive either the modified or standard DHAP regimen. The primary endpoint is overall response rate (ORR) assessed by RECIL 2017 criteria. Secondary endpoints include progression-free survival (PFS), toxicity incidence and severity graded by CTCAE, and quality of life measured by EORTC QLQ-C30. The study anticipates that the modified DHAP regimen will demonstrate comparable or superior efficacy with reduced severe toxicities, shorter hospital stays, and improved patient satisfaction. Findings may support transitioning DHAP into outpatient administration, optimizing healthcare resource utilization in Pakistan.
Take a new drug combined with chemotherapy for T-cell lymphoma
In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
Find Non-hodgkin Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.